-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $15

Benzinga·11/11/2026 14:24:02
Piper Sandler analyst Biren Amin maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $21 to $15.